Andy Chen
Analyst
Wolfe Research
Equibles does not estimate personal net worth.
About Andy Chen
Andy Chen is recorded as Analyst at Wolfe Research. Andy Chen has spoken on 4 earnings calls and 1 other investor event across 4 companies, most recently for Sarepta Therapeutics, Inc. on August 5, 2026. Those appearances were for Sarepta Therapeutics, Inc. (SRPT), Madrigal Pharmaceuticals, Inc. (MDGL), Crinetics Pharmaceuticals, Inc. and Anaptysbio, Inc (ANAB). The companies whose calls Andy Chen spoke on are classified in the Healthcare sector.
Andy Chen on recent calls
“Regarding the math data in DM1 with the functional endpoint, I think, Luis, you mentioned that the goal is not, or the primary goal is not to establish functional efficacy with the data set.”
“So we noticed that you provided timeline guidance on the oral GLP-1 and the D-Guide-2. Just curious, can you maybe tell us a bit more about the Arrowhead asset?”
“Just curious if you can comment on your competition's growth, a recent revenue trajectory in CAH. What do you think is happening here? Do you feel like you have a greater opportunity, or do you think you have a lesser opportunity given the recent trajectory?”
“So I imagine if you're looking for a deal with another partner and that deal probably has to come to fruition before your intended separation, and you have your intended separation by year end, 2026, does that mean you're confident that an attractive deal will be available by that time?”
Affiliation history
-
Wolfe Research
Analyst
Transcript header (unverified)
Current
Company network
Crinetics Pharmaceuticals, Inc.
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-02-26
Anaptysbio, Inc
ANAB
Biotechnology · Healthcare
1 appearance
Latest appearance 2025-09-29
View calls and events
Recent activity
-
-
-
Earnings call
Crinetics Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Crinetics Pharmaceuticals, Inc.
-
-